Xiaowei Yu

Xiaowei Yu, Zhe Huang, Minheng Chen et al.

We investigate the impact of entropy change in deep learning systems by noise injection at different levels, including the embedding space and the image. The series of models that employ our methodology are collectively known as Noisy Neural Networks (NoisyNN), with examples such as NoisyViT and NoisyCNN. Noise is conventionally viewed as a harmful perturbation in various deep learning architectures, such as convolutional neural networks (CNNs) and vision transformers (ViTs), as well as different learning tasks like image classification and transfer learning. However, this work shows noise can be an effective way to change the entropy of the learning system. We demonstrate that specific noise can boost the performance of various deep models under certain conditions. We theoretically prove the enhancement gained from positive noise by reducing the task complexity defined by information entropy and experimentally show the significant performance gain in large image datasets, such as the ImageNet. Herein, we use the information entropy to define the complexity of the task. We categorize the noise into two types, positive noise (PN) and harmful noise (HN), based on whether the noise can help reduce the task complexity. Extensive experiments of CNNs and ViTs have shown performance improvements by proactively injecting positive noise, where we achieved an unprecedented top 1 accuracy of 95$\%$ on ImageNet. Both theoretical analysis and empirical evidence have confirmed that the presence of positive noise, can benefit the learning process, while the traditionally perceived harmful noise indeed impairs deep learning models. The different roles of noise offer new explanations for deep models on specific tasks and provide a new paradigm for improving model performance. Moreover, it reminds us that we can influence the performance of learning systems via information entropy change.

Jing Zhang, Xiaowei Yu, Tong Chen et al.

The Lewy body dementia (LBD) is the second most common neurodegenerative dementia after Alzheimer's disease (AD). Early differentiation between AD and LBD is crucial because they require different treatment approaches, but this is challenging due to significant clinical overlap, heterogeneity, complex pathogenesis, and the rarity of LBD. While recent advances in artificial intelligence (AI) demonstrate powerful learning capabilities and offer new hope for accurate diagnosis, existing methods primarily focus on designing "neural-level networks". Our work represents a pioneering effort in modeling system-level artificial neural network called BrainNet-MoE for brain modeling and diagnosing. Inspired by the brain's hierarchical organization of bottom-up sensory integration and top-down control, we design a set of disease-specific expert groups to process brain sub-network under different condition, A disease gate mechanism guides the specializa-tion of expert groups, while a transformer layer enables communication be-tween all sub-networks, generating a comprehensive whole-brain represen-tation for downstream disease classification. Experimental results show superior classification accuracy with interpretable insights into how brain sub-networks contribute to different neurodegenerative conditions.

Xiaowei Yu, Jing Zhang, Tong Chen et al.

Lewy Body Disease (LBD) is a common yet understudied form of dementia that imposes a significant burden on public health. It shares clinical similarities with Alzheimer's disease (AD), as both progress through stages of normal cognition, mild cognitive impairment, and dementia. A major obstacle in LBD diagnosis is data scarcity, which limits the effectiveness of deep learning. In contrast, AD datasets are more abundant, offering potential for knowledge transfer. However, LBD and AD data are typically collected from different sites using different machines and protocols, resulting in a distinct domain shift. To effectively leverage AD data while mitigating domain shift, we propose a Transferability Aware Transformer (TAT) that adapts knowledge from AD to enhance LBD diagnosis. Our method utilizes structural connectivity (SC) derived from structural MRI as training data. Built on the attention mechanism, TAT adaptively assigns greater weights to disease-transferable features while suppressing domain-specific ones, thereby reducing domain shift and improving diagnostic accuracy with limited LBD data. The experimental results demonstrate the effectiveness of TAT. To the best of our knowledge, this is the first study to explore domain adaptation from AD to LBD under conditions of data scarcity and domain shift, providing a promising framework for domain-adaptive diagnosis of rare diseases.

Jing Zhang, Xiaowei Yu, Minheng Chen et al.

Integrating brain imaging data with clinical reports offers a valuable opportunity to leverage complementary multimodal information for more effective and timely diagnosis in practical clinical settings. This approach has gained significant attention in brain disorder research, yet a key challenge remains: how to effectively link objective imaging data with subjective text-based reports, such as doctors' notes. In this work, we propose a novel framework that aligns brain connectomes with clinical reports in a shared cross-modal latent space at both the subject and connectome levels, thereby enhancing representation learning. The key innovation of our approach is that we treat brain subnetworks as tokens of imaging data, rather than raw image patches, to align with word tokens in clinical reports. This enables a more efficient identification of system-level associations between neuroimaging findings and clinical observations, which is critical since brain disorders often manifest as network-level abnormalities rather than isolated regional alterations. We applied our method to mild cognitive impairment (MCI) using the ADNI dataset. Our approach not only achieves state-of-the-art predictive performance but also identifies clinically meaningful connectome-text pairs, offering new insights into the early mechanisms of Alzheimer's disease and supporting the development of clinically useful multimodal biomarkers.